The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with Palmitoylethanolamide (PEA). This innovative combination aims to address the complex neurobiological and ...

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

Northwestern University spinout Grove Biopharma, a synthetic biology specialist developing a platform known as Bionic ...

In the heart of Austin, where music and innovation often intersect, beloved local Casey McPherson’s story has struck a chord ...

Shares of Caribou Biosciences (NASDAQ:CRBU) will be in focus on Friday after the gene-editing biotech announced plans to ...

When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...

Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...

Coursera reported quarterly earnings of 12 cents per share which beat the analyst consensus estimate of 8 cents per share.